Latest Conference Coverage

The chairman of the Division of Pediatric Hematology & Oncology and BMT at Cleveland Clinic Children's discussed results from the phase 1/2 RUBY trial he presented at ASH 2025.

ImmunoLogic cohost Janna Minehart, MD, discussed a few exciting immunotherapy sessions she attended at ASH's Annual Meeting.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed findings from a patient population traditionally excluded from clinical trials for CAR-T.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed the institution's experience with integrating use of exa-cel and lovo-cel.

The clinical fellow in hematology/oncology at the University of Pennsylvania discussed several sessions she's excited about at the ASH Annual Meeting.

The associate staff member at the Cleveland Clinic discussed the institution's experience with integrating use of exa-cel and lovo-cel.

Crawford Strunk, MD, an associate staff member at the Cleveland Clinic, discussed a study he presented at ASH’s 2025 Annual Meeting.

The associate staff member at the Cleveland Clinic discussed a study he presented at ASH’s 2025 Annual Meeting.

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

The research director at the Clinic for Special Children discussed how screening at-risk patients can speed up diagnosis and treatment of spinal muscular atrophy.

The NSGC president-elect spoke on the evolving role of genetic counselors, emphasizing personalized care, gene therapy advancements, and the need for multidisciplinary integration in healthcare.

The genetic counselor in the Department of Ophthalmology at the University of Pittsburgh Medical Center discussed the growing role of genetic counselors in guiding patients undergoing gene therapy.

The vice president of Rare Disease Strategy at Worldwide Clinical Trials discussed the increasing importance of genetic counselors in clinical trials with regard to design, execution, and interpretation.

The president of the National Society of Genetic Counselors discussed AI and gene therapy, which constituted key topics at NSGC's annual conference this year.

The senior director of research and real world data at Genome Medical discussed multiple perspectives on how AI may take over some of the roles of genetic counselors in the future.

The senior director of research and real world data at Genome Medical discussed important considerations for genetic counselors thinking about using AI tools in their practice.

The senior director of research and real world data at Genome Medical discussed a session she chaired at the NSGC Annual Conference.

Naji Gehchan, MD, MBA, the chief medical and development officer of Kyverna Therapeutics, went over new data the company presented at AANEM’s 2025 meeting.

The chief medical and development officer of Kyverna Therapeutics went over new data the company presented at AANEM’s 2025 meeting.

It was noted that the CA19-9 reductions in the 5 patients observed after infusion of satri-cel ranged from 51.3% to 96.1%.

The primary end point of the study was met.

Jainu Jogani, the cofounder of Child’s Cure Genetic Research, discussed his daughter’s rare genetic disease and the need for new treatment options.

The cofounder of Child’s Cure Genetic Research discussed his daughter’s rare genetic disease and the need for new treatment options.

Roger Hajjar, MD, the director of the Mass General Brigham Gene and Cell Therapy Institute, discussed a trend of physicians and scientists working on models to make gene therapy products commercially viable.

The director of the Mass General Brigham Gene and Cell Therapy Institute discussed a trend of doctors and scientists working on models to make gene therapy products financially viable.

The director of the Mass General Brigham Gene and Cell Therapy Institute discussed innovations in viral vectors, CAR-T, and more.

The trial, which is taking place in the United States, is expected to enroll 40 patients in total.